Changes of cardiac function in rats with myocardial infarction after umbilical cord-derived mesenchymal stem cell transplantation: A meta-analysis / 中国组织工程研究

ABSTRACT

BACKGROUND: It has been shown that compared with stem cells from other sources, umbilical cord-derived mesenchymal stem cells have lower immunogenicity, and their application has significant effect in rats with myocardial infarction. OBJECTIVE: To systematically evaluate the effects of umbilical cord-derived mesenchymal stem cells on cardiac function of rats with myocardial infarction. METHODS: PubMed, Cochrane, Embase, CBM, CNKI, WanFang, VIP and CJD databases were retrieved for the literature concerning umbilical cord-derived mesenchymal stem cells for treating rats with myocardial infarction published before June 2019. Two researchers independently completed literature screening, data extraction and methodological quality evaluation according to the inclusion criteria. Meta-analysis was conducted on Stata 14.0. RESULTS AND CONCLUSION: A total of 9 articles were included, involving 216 rats. Meta-analysis showed that (1) Umbilical cord-derived mesenchymal stem cells significantly increased the left ventricular ejection fraction after myocardial infarction in rats [95% confidence interval (CI) (3.16, 3.76), P < 0.001]. (2) Umbilical cord-derived mesenchymal stem cells significantly increased the left ventricular short axis shortening rate after myocardial infarction in rats [95%CI (0.18, 0.54), P < 0.001]. (3) Umbilical cord-derived mesenchymal stem cells significantly shortened the left ventricular end-diastolic internal diameter [95%CI (-1.90,-0.99), P=0.042] and left ventricular end-systolic internal diameter [95%CI (-6.56,-4.65), P < 0.001]. (4) Umbilical cord-derived mesenchymal stem cells significantly improved the left ventricular end-diastolic volume [95%CI (-2.01,-1.11), P < 0.001] and left ventricular end-systolic volume [95%CI (-3.44,-2.17), P < 0.001]. In summary, umbilical cord-derived mesenchymal stem cell transplantation is effective and safe in the treatment of myocardial infarction in rats. Due to the limitation of the quality of the included literature, the above conclusions need to be validated by high-quality and large-sample randomized controlled trials.